Condition: Percutaneous Coronary Revascularisation · Complex Coronary Lesion · Sponsor: Isala
ULTRA-CTO is a prospective multicentre non-randomised investigator-initiated trial designed to enrol 200 subjects with an indication for percutaneous coronary intervention (PCI) of chronic total occluded (CTO) coronary artery. The main objective of the study is to assess the predictive value of post-PCI resting full-cycle ratio (RFR) and fractional flow reserve (FFR) with regard to Fractional flow reserve (SSR) in CTO patients.
This description comes directly from the study's public registry record.
Maarten van Leeuwen, PhD · 0031 38 424 2374 · m.a.h.van.leeuwen@isala.nl
Always discuss trial participation with your own doctor first.
| Radboud UMC | Nijmegen, Netherlands | Not Yet Recruiting |
| Isala | Zwolle, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04780971